An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...

Tailoring rituximab treatment among patients with pemphigus based on the presence of predictors of early relapse reduced relapse rates at 12 months.

A new study published in the journal of BMC Nephrology revealed rituximab to be an effective and safe steroid sparing medication in individuals with steroid dependent (SD)/frequent relapsing ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of ...

A new study suggests that a simple treatment algorithm could significantly reduce disparities in multiple sclerosis care ...